- Conditions
- Granuloma Annulare
- Interventions
- Abrocitinib 200 mg
- Drug
- Lead sponsor
- William Damsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
- Interventions
- Corticosteroid with lidocaine, Corticosteroid with normal saline
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Keloid, Scleroderma, Scars, Granuloma Annulare, Acne Keloidalis Nuchae
- Interventions
- German manufactured UVA1 emitting light system
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Keloid, Scleroderma, Localized, Acne Keloidalis, Scars, Granuloma Annulare
- Interventions
- UVB Irradiation
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Sarcoidosis, Granuloma Annulare
- Interventions
- Deucravacitinib
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Granuloma Annulare
- Interventions
- AC-1101
- Drug
- Lead sponsor
- TWi Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Granuloma Annulare
- Interventions
- Not listed
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Cutaneous Sarcoidosis, Granuloma Annulare
- Interventions
- Tofacitinib 5 mg twice daily
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut